QS Investors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

QS Investors’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,200	Closed	-$7K	–	2032
2017 Q2	$7K	Sell	2,200 -62,107	-97%	-$258K	﹤0.01%	1616
2017 Q1	$592K	Hold	64,307	–	–	0.01%	915
2016 Q4	$496K	Hold	64,307	–	–	﹤0.01%	885
2016 Q3	$735K	Hold	64,307	–	–	0.01%	817
2016 Q2	$792K	Hold	64,307	–	–	0.01%	815
2016 Q1	$650K	Hold	64,307	–	–	0.01%	854
2015 Q4	$1.45M	Sell	64,307 -1,763	-3%	-$36.1K	0.01%	721
2015 Q3	$1.1M	Hold	66,070	–	–	0.01%	754
2015 Q2	$1.49M	Buy	66,070 +9,770	+17%	+$241K	0.02%	676
2015 Q1	$1.45M	Hold	56,300	–	–	0.02%	662
2014 Q4	$1.23M	Buy	+56,300	New	+$1.15M	0.01%	688

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

QS Investors's OMED Position: Q3 2017 in Review

QS Investors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2017, closing a stake of 2,200 shares — an estimated $7K sold.

QS Investors first reported a position in OMED in Q4 2014 and held it in 11 quarters. The position peaked at $1.49M in Q2 2015. 58 funds tracked by Wall St. Rank hold OMED as of Q3 2017.

QS Investors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
QS Investors sold 2,200 OncoMed Pharmaceuticals, Inc. shares in Q3 2017, an estimated $7K.
QS Investors first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2014 and held it in 11 quarters.
QS Investors's OncoMed Pharmaceuticals, Inc. position peaked at $1.49M in Q2 2015.
58 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2017.

Based on QS Investors's 13F filing for Q3 2017, filed 14 Nov 2017.